Can arthritis patients stop their meds? study tests if remission can last without treatment.
NCT ID NCT05622708
Summary
This study aims to find out if people with non-radiographic axial spondyloarthritis (a type of inflammatory back disease) need to continue taking the drug secukinumab long-term after their symptoms go away. It will enroll 240 adults whose disease is in remission. The main goal is to see how many people can stay flare-free for about two years if they stop the medication compared to those who continue it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Bruges, 8000, Belgium
-
Novartis Investigative Site
Genk, 3600, Belgium
-
Novartis Investigative Site
Ghent, 9000, Belgium
-
Novartis Investigative Site
Mons, 7000, Belgium
-
Novartis Investigative Site
Juiz de Fora, Minas Gerais, 36010 570, Brazil
-
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, 90480-000, Brazil
-
Novartis Investigative Site
Barretos, São Paulo, 14784 400, Brazil
-
Novartis Investigative Site
Bogota, Cundinamarca, 110111, Colombia
-
Novartis Investigative Site
Bogota, Cundinamarca, 110221, Colombia
-
Novartis Investigative Site
Chía, Cundinamarca, 250001, Colombia
-
Novartis Investigative Site
Bucaramanga, Santander Department, 680003, Colombia
-
Novartis Investigative Site
Prague, 128 00, Czechia
-
Novartis Investigative Site
Prague, 148 00, Czechia
-
Novartis Investigative Site
Prague, 150 06, Czechia
-
Novartis Investigative Site
Uherské Hradiště, 686 01, Czechia
-
Novartis Investigative Site
Chambray-lès-Tours, 37170, France
-
Novartis Investigative Site
Le Mans, 72000, France
-
Novartis Investigative Site
Nice, 06001, France
-
Novartis Investigative Site
Paris, 75012, France
-
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Novartis Investigative Site
Bad Doberan, 18209, Germany
-
Novartis Investigative Site
Berlin, 12161, Germany
-
Novartis Investigative Site
Berlin, 13125, Germany
-
Novartis Investigative Site
Hamburg, 22415, Germany
-
Novartis Investigative Site
Herne, 44649, Germany
-
Novartis Investigative Site
Ratingen, 40878, Germany
-
Novartis Investigative Site
Székesfehérvár, Fejér, 8000, Hungary
-
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, 4032, Hungary
-
Novartis Investigative Site
Kistarcsa, 2143, Hungary
-
Novartis Investigative Site
Miskolc, 3526, Hungary
-
Novartis Investigative Site
Szeged, 6725, Hungary
-
Novartis Investigative Site
Veszprém, 8200, Hungary
-
Novartis Investigative Site
Kfar Saba, 4428164, Israel
-
Novartis Investigative Site
Ramat Gan, 5265601, Israel
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Ancona, AN, 60126, Italy
-
Novartis Investigative Site
Torino, TO, 10128, Italy
-
Novartis Investigative Site
Negrar, VR, 37024, Italy
-
Novartis Investigative Site
Verona, VR, 3712, Italy
-
Novartis Investigative Site
Kuala Lumpur, 59100, Malaysia
-
Novartis Investigative Site
Guadalajara, Jalisco, 44650, Mexico
-
Novartis Investigative Site
Guadalajara, Jalisco, 44690, Mexico
-
Novartis Investigative Site
Mérida, Yucatán, 97070, Mexico
-
Novartis Investigative Site
Chihuahua City, 31000, Mexico
-
Novartis Investigative Site
Heerlen, Limburg, 6419 PC, Netherlands
-
Novartis Investigative Site
Amsterdam, North Holland, 1105 AZ, Netherlands
-
Novartis Investigative Site
Makati City, National Capital Region, 1218, Philippines
-
Novartis Investigative Site
Manila, 1008, Philippines
-
Novartis Investigative Site
Krakow, Lesser Poland Voivodeship, 30-727, Poland
-
Novartis Investigative Site
Bydgoszcz, 85-168, Poland
-
Novartis Investigative Site
Krakow, 30-002, Poland
-
Novartis Investigative Site
Sochaczew, 96-500, Poland
-
Novartis Investigative Site
Torun, 87-100, Poland
-
Novartis Investigative Site
Warsaw, 02-637, Poland
-
Novartis Investigative Site
Cluj-Napoca, Cluj, 400006, Romania
-
Novartis Investigative Site
Bucharest, 011055, Romania
-
Novartis Investigative Site
Bucharest, 011172, Romania
-
Novartis Investigative Site
Bangkok, 10400, Thailand
-
Novartis Investigative Site
Bangkok, 10700, Thailand
-
Novartis Investigative Site
Adana, Yuregir, 01230, Turkey (Türkiye)
-
Novartis Investigative Site
Konya, 42080, Turkey (Türkiye)
-
Novartis Investigative Site
Ho Chi Minh City, VNM, 700000, Vietnam
-
Novartis Investigative Site
Ho Chi Minh City, 700000, Vietnam
Conditions
Explore the condition pages connected to this study.